This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

LAST CHANCE: REGISTER BY MAY 20 TO SAVE UP TO $300

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, California

David Scott
Co-Founder & Head of Innovation at Arbor Biotechnologies

Profile

David co-founded Arbor Biotechnologies to harness the protein diversity of bacterial and viral genomes for best- or first-in-class biotechnologies to power the next generation of genetic medicines. As Head of Research through May 2021, David led Arbor’s scientific team in the development of the company’s high-throughput discovery engine and the discovery of an industry-leading portfolio of next-generation CRISPR gene editing technologies. Currently, as Head of Innovation, David is focused on growing an ecosystem for the expanded use of Arbor’s technologies and sourcing technologies to accelerate the company’s product development. Prior to Arbor, David completed his PhD at MIT in the lab of Feng Zhang at the Broad Institute, where he explored the early applications of CRISPR systems for genome editing.

Agenda Sessions

  • Arbor Biotechnologies Case Study

    9:15am